Jaguar8 commented on a stock · Dec 5, 2024 06:11

NEWS

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Mind Medicine (MindMed) (NASDAQ: MNMD), a clinical-stage biopharmaceutical company, announced that its MM120 Orally Disintegrating Tablet (ODT) has been granted an Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) under the Innovative Licensing and Access Pathway (ILAP). This designation aims to accelerate the time to market and facilitate patient access to MM120 ODT for the treatment of Generalized Anxiety Disorder (GAD). The Innovation Passport provides access to various development tools and opportunities for enhanced regulatory input. Specific benefits include a potential 150-day accelerated Marketing Authorization Application assessment and continuous benefit-risk assessment. This follows the receipt of Breakthrough Therapy Designation by the U.S. FDA, highlighting MM120 ODT's potential to address critical needs in mental health.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

6117 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

6711

Followers

Following

72K

Visitors